Charco Neurotech raises £545k from Crista Galli Ventures and Keith Gibbs to fund product launch
The funding will support the company as it prepares to launch its CUE1 device in the UK and EU markets.
Charco Neurotech is a medical technology company developing a vibrotactile stimulation device to help manage symptoms of Parkinson disease.
Charco Neurotech has secured £545k in funding from Crista Galli Ventures and Keith Gibbs. The capital will be used to launch the company flagship device, the CUE1, in the UK and European Union markets.
The investment will support the firm as it works towards completing CE marking approvals, finalising manufacturing plans, and conducting further clinical trials. The company previously participated in the MedCity Investment Hub.
Use of funds
- 01Expand into international markets
- 02Fund research and development
- 03Build out infrastructure
Investors
Categories
About the company
Charco Neurotech
Charco Neurotech develops medical devices to help manage movement symptoms associated with Parkinson disease.